Travere Therapeutics
TVTX
133 hedge funds and large institutions have $719M invested in Travere Therapeutics in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 39 reducing their positions, and 17 closing their positions.
134% more call options, than puts
Call options by funds: $76.4M | Put options by funds: $32.6M
54% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 39
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
6% more funds holding
Funds holding: 126 → 133 (+7)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
34% less capital invested
Capital invested by funds: $1.09B → $719M (-$373M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$19.7M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$15.2M |
| 3 |
Goldman Sachs
New York
|
+$14.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$14.4M |
| 5 |
BC
Broadfin Capital
New York
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$20.4M |
| 2 |
Millennium Management
New York
|
-$10.9M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$7.55M |
| 4 |
WSA
Wall Street Associates
Lajolla,
California
|
-$7.02M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$5.4M |
TVTX Hedge Fund Activity: Q3 2015 in Review
133 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2015, worth a combined $719M — down 34% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TVTX positions and 17 closed out — a net gain of 8 holders — while 60 added to existing stakes and 39 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $19.7M. The largest seller was Jennison Associates, cutting an estimated $20.4M.
- 133 institutional investors held Travere Therapeutics (TVTX) as of Q3 2015, up from 126 in Q2 2015.
- Funds reported $719M of Travere Therapeutics stock for Q3 2015, down 34% quarter-over-quarter.
- 25 funds opened new Travere Therapeutics positions in Q3 2015 and 17 closed out, a net change of +8 holders.
- The largest Travere Therapeutics buyer in Q3 2015 was EcoR1 Capital, an estimated $19.7M added.
- The largest Travere Therapeutics seller in Q3 2015 was Jennison Associates, an estimated $20.4M sold.
Based on aggregated 13F filings for Q3 2015.